Tech Company Financing Transactions
HiFiBiO Therapeutics Funding Round
HiFiBiO Therapeutics, operating out of Cambridge, secured $67 million from IDG Capital Partners, Delian Capital and Hanne Capital.
Transaction Overview
Company Name
Announced On
8/29/2019
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Series C
Investors
Proceeds Purpose
HiFiBiO Therapeutics will use the proceeds from the financing to expand its platform efforts and accelerate the development of its novel antibody drug pipeline to treat cancer and autoimmune disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
237 Putnam Ave.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Liang Schweizer
Chief Financial Officer
Fred Dom
Chief Financial Officer
Philip Sin
Chief Operating Officer
Jeffrey He
Vice President
Luigi Manenti
VP - Administration
Vincent Tse
VP - General Counsel
Xuqiong Wu
VP - R & D
Francisco Adrian
VP - R & D
Nicola Beltraminelli
Browse more venture capital transactions:
Prev: 8/29/2019: Apollo Endosurgery venture capital transaction
Next: 8/29/2019: VRChat venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs